VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PDEXPro-Dex, Inc.
$61.47$197M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPDEXFinancials

Pro-Dex, Inc. (PDEX) Financials

30Y historyFree accessUpdated daily

Operating margins reached 15.5% in 2026Q3 as the company scaled output, though gross margins remain structurally capped near 30.7%.

PDEX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Sales/Revenue74.64M66.59M53.84M46.09M42.04M42.04M34.83M27.17M22.46M21.94M20.16M13.38M10.81M12.25M17.26M27.11M23.21M21.12M25.13M21.56M17.06M13.83M14.2M11.99M10.53M14.84M26.67M18.34M22.65M19.2M20.8M
Revenue Growth %16.39%23.68%16.83%9.62%0%20.69%28.2%20.95%2.38%8.86%50.62%23.78%-11.73%-29.02%-36.34%16.79%9.89%-15.94%16.52%26.39%23.33%-2.58%18.43%13.91%-29.09%-44.34%45.4%-19.01%17.96%-7.69%131.11%
Cost of Goods Sold53.9M47.08M39.29M33.34M28.91M28.91M21.69M17.39M14.52M14.76M14.76M9.68M7.85M8.53M11.84M16.57M14.85M14.37M16.92M14.2M10.48M6.75M7.39M7.08M6.43M8.09M12.13M9.76M10.02M8.2M7.8M
COGS % of Revenue-70.7%72.98%72.34%68.76%68.76%62.27%64.01%64.64%67.25%73.2%72.32%72.57%69.66%68.62%61.13%63.97%68.05%67.33%65.83%61.46%48.82%52.08%59.01%61.05%54.5%45.46%53.23%44.23%42.71%37.5%
Gross Profit20.73M19.51M14.55M12.75M13.13M13.13M13.14M9.78M7.94M7.19M5.4M3.7M2.97M3.72M5.42M10.54M8.36M6.75M8.21M7.37M6.58M7.08M6.8M4.92M4.1M6.75M14.54M8.58M12.63M11M13M
Gross Margin %27.78%29.3%27.02%27.66%31.24%31.24%37.73%35.99%35.36%32.75%26.8%27.68%27.43%30.34%31.38%38.87%36.03%31.95%32.67%34.16%38.54%51.18%47.92%40.99%38.95%45.5%54.54%46.77%55.77%57.29%62.5%
Gross Profit Growth %-34.08%14.13%-2.92%0%-0.08%34.38%23.13%10.53%33%45.87%24.88%-20.18%-31.39%-48.6%25.97%23.95%-17.8%11.43%12.03%-7.12%4.04%38.45%19.88%-39.3%-53.56%69.54%-32.08%14.82%-15.38%96.97%
Operating Expenses9.93M8.82M7.38M6.99M8.01M8.01M6.08M4.79M4.54M4.34M4.63M4.61M3.78M5.61M6.78M7.29M7.15M7.24M7.75M6.53M5.43M4.79M4.97M4.61M6.24M7.97M10.81M18.83M11.24M10.9M10.5M
OpEx % of Revenue-13.25%13.7%15.16%19.05%19.05%17.46%17.62%20.2%19.77%22.98%34.42%34.96%45.81%39.29%26.9%30.8%34.29%30.86%30.26%31.83%34.61%35.01%38.44%59.23%53.71%40.55%102.68%49.64%56.77%50.48%
Selling, General & Admin6.69M5.18M4.19M4.18M4.99M4.99M3.77M2.91M2.65M3.11M2.78M2.94M2.3M3.82M4.71M4.88M4.67M4.45M5.02M4.05M3.42M3.05M3.18M3.12M4.2M4.68M8.66M8.96M8.93M8.5M8.6M
SG&A % of Revenue-7.79%7.78%9.08%11.88%11.88%10.81%10.7%11.77%14.19%13.79%21.95%21.25%31.19%27.31%17.99%20.12%21.08%19.98%18.79%20.05%22.03%22.41%26.02%39.91%31.51%32.46%48.85%39.42%44.27%41.35%
Research & Development3.23M3.64M3.19M2.8M2.98M2.98M2.31M1.88M1.89M1.23M1.85M1.67M1.48M1.79M2.07M2.42M2.48M2.79M2.73M2.47M2.01M1.74M1.79M1.46M1.54M1.67M1.67M1.7M1.41M1.1M600K
R&D % of Revenue-5.46%5.92%6.08%7.09%7.09%6.65%6.93%8.43%5.58%9.19%12.46%13.71%14.61%11.98%8.91%10.68%13.21%10.87%11.47%11.78%12.58%12.61%12.15%14.68%11.26%6.25%9.27%6.22%5.73%2.88%
Other Operating Expenses000035K35K045K00000000000000032K489K1.62M489K8.17M905.44K1.3M1.3M
Operating Income10.81M10.69M7.17M5.76M5.12M5.12M7.07M5M2.39M2.73M526K-902K-814K-1.9M-1.36M3.24M-3.23M-1.49M456K842K1.15M2.29M1.83M306K-2.13M-1.22M3.73M-10.25M1.39M100K2.5M
Operating Margin %14.48%16.05%13.32%12.5%12.19%12.19%20.28%18.39%10.65%12.46%2.61%-6.74%-7.53%-15.47%-7.91%11.97%-13.92%-7.06%1.81%3.9%6.72%16.57%12.91%2.55%-20.28%-8.21%13.99%-55.9%6.12%0.52%12.02%
Operating Income Growth %-49.02%24.49%12.47%0%-27.5%41.38%108.95%-12.51%419.77%158.31%-10.81%57.04%-38.83%-142.08%200.43%-116.49%-427.19%-45.84%-26.53%-50%25.04%499.02%114.33%-75.14%-132.68%136.38%-839.5%1286.61%-96%177.78%
EBITDA12.72M11.93M8.33M6.62M5.85M5.85M7.68M5.44M2.95M3.29M1.13M-324K-287K-1.31M-718K3.94M-2.5M-682K994K1.33M1.5M2.64M2.19M681K-1.27M-261K4.93M-8.82M2.9M1.6M3.8M
EBITDA Margin %17.05%17.91%15.48%14.36%13.91%13.91%22.05%20.01%13.13%14.99%5.6%-2.42%-2.65%-10.72%-4.16%14.54%-10.79%-3.23%3.96%6.16%8.8%19.08%15.46%5.68%-12.07%-1.76%18.47%-48.11%12.82%8.33%18.27%
EBITDA Growth %6.48%43.14%25.9%13.16%0%-23.84%41.28%84.33%-10.34%191.32%448.46%-12.89%78.14%-82.87%-118.22%257.39%-267.16%-168.61%-25.21%-11.52%-43.11%20.27%222.32%153.62%-386.59%-105.3%155.82%-403.98%81.42%-57.89%245.45%
D&A (Non-Cash Add-back)1.92M1.24M1.16M857K726K726K614K438K557K555K603K578K527K582K647K697K726K810K538K487K356K348K362K375K865K958K1.2M1.43M1.52M1.5M1.3M
EBIT11.81M12.89M3.19M9.96M6.16M6.16M8.14M4.99M3.4M2.85M1.17M-440K-747K-1.89M-1.36M3.48M-3.19M-1.48M499K842K1.15M2.29M1.83M306K-2.13M-1.22M1.67M-10.25M1.39M100K2.5M
Net Interest Income-473K-747K-414K-239K-388K-226K-141K48K218K15K-37K04K-8K-36K-148K-202K-226K-164K000000000000
Interest Income95K82K144K294K76K126K95K268K225K27K06K12K3K002K2K17M000000000000
Interest Expense367K829K558K533K464K352K236K220K7K12K37K6K8K11K36K148K204K228K181K0021M000000000
Other Income/Expense5.28M1.37M-4.54M3.67M571K571K836K449K218K15K602K456K59K-8K-36K-382K-4.6M-1.21M-138K-267K7K138K69K-51K-240K-907K-1.02M-971K-881.98K-1.2M-1M
Pretax Income16.09M12.06M2.63M9.43M5.69M5.69M7.9M5.45M2.61M2.75M847K-446K-755K-1.9M-1.4M3.1M-3.39M-1.7M318K575K1.15M2.43M1.9M255K-2.38M-2.13M2.6M-11.22M504.63K-1.1M1.5M
Pretax Margin %21.56%18.11%4.89%20.46%13.54%13.54%22.68%20.05%11.62%12.54%4.2%-3.33%-6.98%-15.54%-8.12%11.42%-14.6%-8.07%1.27%2.67%6.76%17.57%13.39%2.13%-22.56%-14.32%9.74%-61.2%2.23%-5.73%7.21%
Income Tax4.09M3.08M507K2.35M1.12M1.12M1.79M1.3M989K-2.09M25K-44K-104K-39K-441K456K-420K1.14M1K69K326K581K782K122K-1.21M-829K1.06M-2.29M151.07K-300K300K
Effective Tax Rate %25.41%25.54%19.25%24.97%19.7%19.7%22.65%23.85%37.89%-75.91%2.95%9.87%13.77%2.05%31.48%14.73%12.4%-66.96%0.31%12%28.27%23.91%41.11%47.84%50.95%38.99%40.71%20.41%29.94%27.27%20%
Net Income12M8.98M2.13M7.07M4.57M4.57M6.11M4.15M1.62M5.08M822K-365K-488K-1.78M-876K2.64M-2.97M-2.85M317K506K827K1.85M1.12M133K-1.57M2.85M1.54M-8.93M353.56K-1.6M1.2M
Net Margin %16.08%13.48%3.95%15.35%10.88%10.88%17.55%15.27%7.22%23.17%4.08%-2.73%-4.51%-14.56%-5.08%9.74%-12.79%-13.47%1.26%2.35%4.85%13.37%7.89%1.11%-14.88%19.18%5.78%-48.71%1.56%-8.33%5.77%
Net Income Growth %28.11%322.1%-69.93%54.72%0%-25.2%47.35%155.89%-68.12%518.49%325.21%25.2%72.65%-103.65%-133.18%188.95%-4.32%-997.48%-37.35%-38.81%-55.27%65.09%742.11%108.49%-155.01%84.75%117.25%-2626.87%122.1%-233.33%300%
Net Income (Continuing)12M8.98M2.13M7.07M4.57M4.57M6.11M4.15M1.62M4.84M1.1M-402K-651K-1.86M-960K2.8M-2.97M-2.85M317K506K827K1.85M1.12M133K-1.17M-1.3M389K-8.93M353.56K-900K1.2M
Discontinued Operations000000000243K037K163K000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)3.672.670.601.951.211.131.500.970.371.250.20-0.09-0.14-0.54-0.270.80-0.92-0.880.100.160.250.570.360.04-0.530.970.52-3.050.12-0.530.43
EPS Growth %29.29%345%-69.23%61.16%7.08%-24.67%54.64%162.16%-70.4%525%328.57%37.5%74.07%-100%-133.75%186.96%-4.55%-1018.58%-40.13%-36%-56.14%58.33%716.33%108.32%-154.64%86.54%117.05%-2641.67%122.64%-223.26%186.67%
EPS (Basic)-2.730.611.981.261.171.560.990.381.260.20-0.09-0.14-0.54-0.270.81-0.92-0.880.100.160.260.610.380.05-0.530.970.53-3.060.12-0.530.43
Diluted Shares Outstanding3.27M3.36M3.57M3.64M3.76M3.94M4.08M4.3M4.34M4.08M4.17M4.17M3.49M3.32M3.27M3.29M3.23M3.24M3.31M3.25M3.33M3.22M3.11M3.01M2.93M2.93M2.98M2.93M2.97M3.03M2.82M
Basic Shares Outstanding3.2M3.29M3.5M3.57M3.64M3.8M3.91M4.19M4.3M4.04M4.14M4.02M3.49M3.32M3.27M3.26M3.23M3.24M3.25M3.19M3.17M3.04M2.93M2.91M2.93M2.93M2.93M2.92M2.95M3M2.82M
Dividend Payout Ratio-------0.55%-----------------------

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Extreme customer concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Sustained Revenue Expansion Amid Volatility

According to the provided quarterly income statements, PDEX has demonstrated consistent top-line growth, culminating in a 14.6% year-over-year revenue increase to $19.9 million in 2026Q3, suggesting that the company's integration into OEM surgical platforms is successfully driving sustained demand for its specialized medical components.

The revenue trajectory appears to be supported by the multi-year lifecycles of the surgical systems PDEX supports, which provides a degree of insulation from broader industrial cyclicality. However, investors should monitor the lumpiness in quarterly growth rates, which may reflect the timing of specific engineering milestones or OEM product launch cycles rather than purely organic volume expansion.

Structural Constraints on Margin Expansion

As reported in financial statements, PDEX maintains a gross margin profile of approximately 30%, which, while stable, remains significantly lower than pure-play medtech peers, indicating that the company's role as a specialized contract manufacturer limits its ability to capture the full premium pricing of end-market surgical devices.

The gross margin volatility observed in 2025Q4, where it dipped to 19.9%, highlights the sensitivity of the cost structure to production inefficiencies or potential supply chain disruptions. Without a shift toward higher-margin proprietary intellectual property, the current margin ceiling appears to be a structural feature of the OEM-partner business model.

Operating Leverage Scaling With Revenue

Based on the income statement data, PDEX has successfully managed its SG&A expenses relative to revenue growth, with operating margins reaching 15.5% in 2026Q3, suggesting that the company is achieving meaningful operating leverage as it scales its specialized manufacturing output for its primary medical OEM partners.

The ability to keep SG&A growth below the rate of revenue expansion indicates disciplined overhead management, which is critical given the company's relatively thin gross margin profile. Continued monitoring of this relationship is warranted to ensure that future revenue gains are not eroded by rising administrative or compliance-related costs.

Earnings Quality and Liquidity Concerns

Analysis of the reported figures reveals a significant discrepancy between net income and cash availability, as the company reported $3.9 million in net income for 2026Q3 while maintaining a cash balance of only $419,000, which warrants further investigation into the company's working capital and cash conversion cycle.

The high net income relative to the minimal cash position suggests that earnings may be heavily tied to accounts receivable or inventory buildup, which could pose liquidity risks if OEM payment cycles extend. Investors should be cautious of the quality of these earnings, as they may not be fully representative of the company's immediate ability to fund operations without external financing.

Risks of OEM Dependency and Liquidity

While PDEX exhibits strong growth, the combination of extreme customer concentration and a razor-thin cash buffer of $419,000, as noted in recent filings, suggests that the company is highly vulnerable to any sudden shifts in OEM order volumes or delays in the regulatory clearance of partner products.

Short-term volatility in earnings, such as the 56.2% EPS decline observed in 2024Q4, underscores the potential for rapid margin compression if production volumes fall below the threshold required to cover fixed manufacturing costs. The lack of a substantial cash cushion leaves little room for error in managing the working capital requirements of its high-precision manufacturing operations.

PDEX — Frequently Asked Questions

Quick answers to the most common questions about buying PDEX stock.

What was Pro-Dex, Inc.'s (PDEX) revenue in 2025?

For fiscal year 2025, Pro-Dex, Inc. (PDEX) reported total revenue of $66.6M. This represents a 220.2% increase compared to $20.8M in 1996.

Is Pro-Dex, Inc. (PDEX) profitable?

Pro-Dex, Inc. (PDEX) is profitable, generating $9.0M in net income for the fiscal year ending 2025 with a net profit margin of 13.5%.

What is Pro-Dex, Inc.'s operating profit margin?

Pro-Dex, Inc. (PDEX) reported an operating income of $10.7M, resulting in an operating profit margin of 16.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Pro-Dex, Inc.'s gross profit and gross margin?

Pro-Dex, Inc. (PDEX) generated $19.5M in gross profit for the year, representing a gross profit margin of 29.3%. This demonstrates the company's core pricing power and production efficiency.